Fig 1: Treatment responsiveness with regard to ARID1a and RIF1 gene expression. Relapse-free survival for six months upon platinum and taxane treatment in EOC patients (n = 118) is shown. Panel (A) shows ARID1a expression levels by treatment response status. Panel (B) presents a Receiver Operating Characteristic analysis evaluating the utility of ARID1A expression in differentiating treatment responders from non-responders. Utilizing the Youden Index to identify the optimal diagnostic threshold ($cutoff = 50$), the analysis yielded a sensitivity of 0.58 and a specificity of 0.46. Correspondingly, Panel (C) depicts RIF1 expression levels according to clinical response. Panel (D) illustrates the ROC performance of RIF1 mRNA in predicting therapeutic outcomes; at an optimized cutoff of 466, the marker demonstrated a sensitivity of 0.55 and a specificity of 0.57. The strongest cutoff values were determined using the Youden Index. The two cohorts (responders vs. non-responders) are compared using the Mann–Whitney test and the ROC test in the R statistical environment. Statistical significance was set at p < 0.05.
Fig 2: Protein expression of BAF250a and RIF1. Panel (A) shows representative microscopic images of H&E-stained and immunohistochemical (IHC) protein staining in EOC samples, with positive (brownish stain) BAF250a and RIF1 protein expression. Panel (B) shows representative microscopic images of H&E-stained and representative IHC protein staining in Endometrioma samples, with positive (brownish stain) BAF250a and RIF1 protein expression. Panel (C) shows the quantitative analyses of protein expression for BAF250a and RIF1. The white scale bar in the lower left corner indicates 80 μm. The p-value of < 0.0001 is indicated by ****.
Fig 3: Kaplan–Meier survival curves with regard to ARID1a and RIF1 expression in stage IV endometrioid ovarian cancer patients. Panel (A) shows the survival probability by ARID1a expression status. Kaplan–Meier survival curves stratified by low (black) and high (red) ARID1a gene expression. Panel (B) shows the survival probability by RIF1 expression status. Kaplan–Meier survival curves stratified by low (black) and high (red) RIF1 gene expression. Numbers at risk are shown below the plots. Hazard ratios (HRs), 95% confidence intervals, and log-rank p values are indicated.
Fig 4: Differential expression of ARID1a and RIF1 according to the four most significant gene mutations in ovarian cancer. Boxplots depict the expression levels in the tested cohort (n = 272) for mutant versus wild-type tumors. This analysis has been performed in a mixed ovarian cancer cohort and was not restricted to EOC. Panel (A) shows ARID1a messenger RNA expression stratified by BRCA1, GRIN2B, KIF17, and TUBGCP4 mutation status with the respective p-values on the top. Panel (B) shows RIF1 messenger RNA expression stratified by ZNF441, LAMB3, PNPLA6, and LNX1 mutation status, with the respective p-values on the top. The Mann–Whitney analysis was used.
Supplier Page from Abcam for Anti-Rif1 antibody